The most important story this quarter didn’t happen at home.
When overseas execution starts driving results, it usually changes the stock’s path before we can fully catch on.
In partnership with
$1K Could’ve Made $2.5M
In 1999, $1K in Nvidia’s IPO would be worth $2.5M today. Now another early-stage AI tech startup is breaking through—and it’s still early.
RAD Intel’s award-winning AI platform helps Fortune 1000 brands predict ad performance before they spend.
The company’s valuation has surged 4900% in four years* with over $50M raised.
Already trusted by a who’s-who roster of Fortune 1000 brands and leading global agencies. Recurring seven-figure partnerships in place and their Nasdaq ticker is reserved: $RADI.
This is a paid advertisement for RAD Intel made pursuant to Regulation A+ offering and involves risk, including the possible loss of principal. The valuation is set by the Company and there is currently no public market for the Company's Common Stock. Nasdaq ticker “RADI” has been reserved by RAD Intel and any potential listing is subject to future regulatory approval and market conditions. Investor references reflect factual individual or institutional participation and do not imply endorsement or sponsorship by the referenced companies. Please read the offering circular and related risks at invest.radintel.ai.
International Momentum Sets the Pace
You’re staring at a quarter in which Cooper Companies Inc. (NASDAQ: COO) relied on its international business to carry the load while the domestic side kept things steady.
EMEA is giving you clean, consistent demand that actually feels durable instead of cyclical noise, and that’s where the real momentum sits.
APAC surprised to the upside but still comes with a side of mixed signals, so you’re not treating that as a green light just yet.
The headline number barely matters here.
What you should care about is the source of the growth, how repeatable it looks, and what this mix says about the runway ahead.
COO is leaning into the regions that are responding strongest, and that shift is tightening the company’s overall trajectory in a way that matters for your next move.
Action: Lean into the international upside by accumulating on dips near the 50-day average because analysts now see upside targets on strong EMEA execution.
Use the next earnings beat as a confirmation to add more and tighten stops below the $72 zone.o take]
High Upside (Sponsored)
Every market cycle produces a select group of companies that drastically outperform the rest.
The latest screening has pinpointed the 5 Stocks Set to Double, each showing rare traits linked to early stage momentum.
These names carry the same type of indicators that have historically appeared ahead of strong rallies.
Earlier reports featured stocks that delivered +175%, +498%, and +673%.
Get the Free 5 Stocks Set to Double Report.
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
The Math Behind the International Momentum
If you’re viewing COO and thinking the stock hasn’t fully caught up to what’s happening overseas, you’re reading it right.
The international business is tightening its grip, the product mix is gaining traction, and the stock is acting like it hasn’t noticed the growth in EMEA and the slight upside in APAC.
Momentum is building, the global footprint is sharpening its edge, and the gap between what the business is doing and how the market prices it is wide enough for you to position yourself now.
Here’s what you should be noticing:
EMEA Strength: The region is performing ahead of expectations, providing a reliable engine for global revenue and showing repeatable growth patterns.
APAC Surprises: Softer on a year-over-year basis but beating estimates, keeping it in play as a potential upside contributor when the region stabilizes.
Revenue Mix: International revenue is carrying more of the quarter’s lift than domestic, highlighting where the real story is unfolding.
Momentum Alignment: The fundamentals from overseas are finally lining up with price movement, creating a window where operational strength and market recognition are moving in the same direction.
This gap between performance and pricing isn’t subtle, and it hasn’t closed yet.
As long as EMEA continues its steady growth and APAC doesn’t falter, this is the kind of setup that demands attention.
Action: TPosition selectively while price is below the median target (~$90) — that gap signals the market isn’t pricing in global strength yet.
Add incremental exposure if shares reclaim $85 on volume, and pause if it fails to hold above that level next week.
AI Growth (Sponsored)
A rapid acceleration in AI deployment across the U.S. is creating fresh opportunities for forward-looking investors.
A free breakdown uncovers 9 companies demonstrating measurable growth and deep alignment with this next wave of AI demand.
These aren’t speculative plays—they are firms with proven traction and expanding AI footprints.
Early movers may see the greatest advantage.
Download the Free Report
Why COO Still Isn’t Getting Full Credit
You’re looking at a company where the international business is stronger than the stock price is showing.
EMEA is holding steady, APAC is beating expectations despite some softness, and lens demand is picking up, yet the stock is moving cautiously.
That leaves a gap between what the COO is doing and how the market is valuing it.
Momentum is building overseas, and you’re in a position to act before the market fully catches on.
Momentum Building: EMEA and global lens sales are firming, signaling that COO is consolidating strength and setting up for smoother growth ahead.
Price vs Performance Disconnect: The stock is acting conservative while the underlying international business accelerates, leaving a gap that won’t last once the trend becomes obvious.
Execution Strength: Lens mix, surgical products, and operational execution are all hitting their marks, giving you solid support even before the broader market notices.
Market Attention Delay: The stock hasn’t fully priced in international traction, so you get a window to position yourself while the story unfolds.
All of these points together show that COO’s international momentum is real, measurable, and ready to push the stock higher once the broader market catches on.
Action: Tilt exposure toward international growth by scaling in only above confirmed support (~$75) and trimming if price falls under $70 on heavy volume.
Analysts raised targets, and EPS beat expectations, so maintain core holdings while these stay intact.
Don’t Let These Undervalued Stocks Slip Through Your Fingers!
We now send our favorite value picks via text, too, so you’ll get the same actionable news without having to open your inbox.
Peer Check: Where COO Stands
The Cooper Companies is gaining traction while many peers in medtech and adjacent categories are dealing with uneven growth and volatile results.
You’re seeing COO’s consistent execution and operational improvements give it a clearer footing, letting it stand out in a crowded, unpredictable landscape.
Improving Footing: COO is moving steadily ahead while competitors struggle, showing that disciplined execution and strong fundamentals make a real difference in performance.
Execution Edge: Operational control, product mix, and international revenue stability reinforce COO’s relative strength compared with peers still finding their rhythm.
Momentum Lead: Growth in premium lenses and consistent execution in surgical products are helping COO pull ahead while other companies are reacting to shifting demand, giving you a visible performance advantage.
Taken together, these trends put COO in a class of its own, delivering consistent performance while much of the sector works to stabilize.
Action: Keep your position as long as COO outperforms peers in execution and international revenue growth, and use relative strength breakouts over $88 to scale up.
If broader medtech starts outperforming COO instead, tighten risk controls accordingly.
Sector Tailwinds and What’s Steering the Shift
The global demand for contact lenses and surgical products is moving steadily higher, reshaping how you track growth in eye care and women’s health.
Premium daily lenses, multifocals, and specialty surgical devices are all seeing broader adoption, and COO is well-positioned to capture this expansion with its combined CooperVision and CooperSurgical offerings.
Global Adoption: You’re seeing COO’s products used across multiple regions, proving that hospitals, clinics, and optometrists are embracing premium lenses and specialty surgical solutions for better outcomes and efficiency.
Expanding Use Cases: From premium daily lenses to fertility and surgical products, the applications are broadening, giving you multiple angles to follow growth.
Multi-Category Strength: COO is delivering across contact lenses and surgical solutions, letting you track leadership and execution across every major segment of the business.
These trends confirm strong sector momentum, positioning COO as a key player benefiting from structural growth in both eye care and surgical markets.
Action: Use structural lens & surgical demand catalysts to guide buys: add exposure on pullbacks that hold, with a tactical sell/trim where high analyst targets cluster.
Let global adoption trends guide your entries.
Trivia: What do we call engraved or embossed lines on coins to prevent shaving off metal?
The Trade-Off: Balancing Stability and Opportunity
COO is delivering steady performance, but there are still bumps to navigate.
International demand is holding, premium lens adoption is strong, and surgical products are gaining traction, yet softness in APAC e-commerce and slower CSI growth create near-term noise.
The stock is pricing in much of that caution, giving you a foundation to work with while the broader story unfolds.
Supply chains are stabilising, execution is on track, and operational discipline continues to support the company’s position.
Cost Pressure: APAC softness and CSI headwinds could weigh on near-term results, but stable operations and product mix keep the downside manageable.
Execution Risk: Lens production, surgical deliveries, and global distribution are all on course, ensuring momentum continues despite regional volatility.
Downside Cushion: Current pricing already factors in some caution, giving you a buffer while fundamentals continue to strengthen.
Upside Bias: Strong EMEA performance, consistent CVI growth, and improving surgical adoption create a runway for upside as the market gradually recognizes COO’s operational strength.
Altogether, COO balances steady execution with growth potential, giving you a clear path to benefit from gains while navigating regional and segment fluctuations.
Action: Focus on COO’s execution across CVI and international markets to capture immediate upside.
Let consistent operational performance guide your positioning while APAC and CSI trends clarify.
Final Word: COO’s Global Play Is the Real Story
Here’s the bottom line: you’re looking at a company where the international business is carrying most of the momentum and doing the heavy lifting for the stock right now.
While it contributes to the top line, fluctuations in e-commerce and regional demand make it unpredictable, so keep an eye on this region for potential surprises.
Taken together, COO’s international footprint isn’t just supporting growth; it’s shaping the stock’s trajectory and giving the company a durable edge over peers.
Near-term earnings may wobble due to regional and segment-specific factors, but the long-term setup built on international execution, CVI momentum, EMEA stability, and surgical traction remains solid.
Watching these factors together gives you a clear picture of a company where the fundamentals are leading the narrative, and the stock’s trajectory is likely to follow as global demand trends continue to unfold.
Setup Scorecard
Entry Window: COO is holding gains with strong international momentum and CVI growth, giving you a clear point to engage with the story.
Catalyst Watch: Track premium lens adoption, EMEA consistency, APAC shifts, and surgical product uptake. These are the key levers driving near-term performance.
Upside Setup: Continued CVI strength, EMEA stability, and growing surgical traction create upward pressure, showing where the stock could move next.
Downside Cushion: The current valuation already prices in some caution, and steady fundamentals across regions provide a solid floor under the stock.
What Moves It Now: Watch EMEA sales trends, APAC recovery signals, CVI product mix, and surgical segment execution to see where momentum is building and where opportunities could appear.
That's our coverage for today; thanks for reading! Reply to this email with feedback or any value names you'd like us to dig into.
Best Regards,
—Noah Zelvis
Undervalued Edge
